Genome & Company Statistics

Total Valuation

Genome & Company has a market cap or net worth of KRW 90.43 billion. The enterprise value is 87.83 billion.

Market Cap	90.43B
Enterprise Value	87.83B

Important Dates

The last earnings date was Thursday, November 14, 2024.

Earnings Date	Nov 14, 2024
Ex-Dividend Date	n/a

Share Statistics

Genome & Company has 30.97 million shares outstanding. The number of shares has increased by 3.64% in one year.

Current Share Class	n/a
Shares Outstanding	30.97M
Shares Change (YoY)	+3.64%
Shares Change (QoQ)	+11.71%
Owned by Insiders (%)	21.52%
Owned by Institutions (%)	0.71%
Float	18.01M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	3.56
PB Ratio	1.53
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-2.32
EV / Sales	3.67
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-2.41

Financial Position

The company has a current ratio of 3.75, with a Debt / Equity ratio of 0.25.

Current Ratio	3.75
Quick Ratio	3.48
Debt / Equity	0.25
Debt / EBITDA	n/a
Debt / FCF	-0.76
Interest Coverage	-14.96

Financial Efficiency

Return on equity (ROE) is -32.39% and return on invested capital (ROIC) is -18.08%.

Return on Equity (ROE)	-32.39%
Return on Assets (ROA)	-15.59%
Return on Capital (ROIC)	-18.08%
Revenue Per Employee	n/a
Profits Per Employee	n/a
Employee Count	n/a
Asset Turnover	0.14
Inventory Turnover	2.90

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -51.90% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-51.90%
50-Day Moving Average	3,669.80
200-Day Moving Average	4,298.55
Relative Strength Index (RSI)	30.25
Average Volume (20 Days)	345,013

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Genome & Company had revenue of KRW 23.92 billion and -37.88 billion in losses. Loss per share was -1,297.31.

Revenue	23.92B
Gross Profit	12.20B
Operating Income	-41.79B
Pretax Income	-42.22B
Net Income	-37.88B
EBITDA	-33.81B
EBIT	-41.79B
Loss Per Share	-1,297.31

Full Income Statement

Balance Sheet

The company has 84.38 billion in cash and 27.71 billion in debt, giving a net cash position of 56.67 billion or 1,829.86 per share.

Cash & Cash Equivalents	84.38B
Total Debt	27.71B
Net Cash	56.67B
Net Cash Per Share	1,829.86
Equity (Book Value)	112.49B
Book Value Per Share	1,910.99
Working Capital	68.58B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -18.91 billion and capital expenditures -17.48 billion, giving a free cash flow of -36.39 billion.

Operating Cash Flow	-18.91B
Capital Expenditures	-17.48B
Free Cash Flow	-36.39B
FCF Per Share	-1,174.88

Full Cash Flow Statement

Margins

Gross margin is 51.00%, with operating and profit margins of -174.67% and -158.35%.

Gross Margin	51.00%
Operating Margin	-174.67%
Pretax Margin	-176.47%
Profit Margin	-158.35%
EBITDA Margin	-141.30%
EBIT Margin	-174.67%
FCF Margin	-152.09%

Dividends & Yields

Genome & Company does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-3.64%
Shareholder Yield	-3.64%
Earnings Yield	-44.43%
FCF Yield	-40.24%

Stock Splits

The last stock split was on August 6, 2024. It was a forward split with a ratio of 2.

Last Split Date	Aug 6, 2024
Split Type	Forward
Split Ratio	2

Scores

Genome & Company has an Altman Z-Score of -0.58. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-0.58
Piotroski F-Score	n/a